ASCO 2021 – Guardant Health – LUNAR-2 Assay

Returning guest, Dr. Kathryn Lang, VP of Outcomes and Evidence at Guardant Health discusses the recent data shared at the 2021 American Society of Clinical Oncology (ASCO) on the investigational blood-based LUNAR-2 assay.  This data shows that it offers a high sensitivity in detecting colorectal cancer (CRC) in asymptomatic patients. This is particularly important now that the U.S. Preventive Services Task Force announced it has lowered the age for CRC screening from 50 to 45. 

Dr. Kathryn Lang is a board certified hemato-oncologist, who completed clinical training in London, UK. With a strong focus on outcomes research throughout her career and over 50 publications, Dr. Lang moved to an industry role with Pfizer in 2016 where she led the global data science initiatives and developed regulatory grade observational research within Pfizer Oncology. She moved to her current role with Guardant Health in 2018 where she is VP of Outcomes and Evidence focusing on early detection of cancer and applied health economics and outcomes research. She is the principal investigator of ECLIPSE, the prospective, multi-site, observational study which is currently enrolling and aims to recruit 10,000 subjects to provide the clinical validation cohort for the LUNAR-2 colorectal cancer screening assay developed by Guardant Health.

Listen on Soundcloud.

Liked it? Take a second to support healthprofessionalradio on Patreon!


Leave a Reply

You must be logged in to post a comment.